BioSpace News Archive

Drug Development

October 26 Research Roundup: New Cell Structures, Herpes and Alzheimer’s, Metformin Mechanism and How to Double Your Lifespan

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

October 24, 2018
·
6 min read
·
Mark Terry
Apogenix to Present at Five Upcoming October and November 2018 International Conferences

Apogenix announced today that company representatives will attend several upcoming international conferences. In a total of five presentations, Apogenix will give updates on its hexavalent TNF superfamily receptor agonists (HERA-ligands) as well as its phase III-ready lead drug candidate asunercept.

October 24, 2018
·
3 min read
Policy

Ministry of Health and Prevention to showcase smart health services at GITEX Technology Week 2018

Smart services to be showcased include electronic sick leave attestation, online permits for imported drugs, ‘Sanad &Rahma’ & electronic birth and death certificates

October 24, 2018
·
1 min read
Deals

Osmotica Pharmaceuticals plc Announces Pricing of Initial Public Offering

Osmotica Pharmaceuticals plc today announced the pricing of its initial public offering of 6,650,000 ordinary shares at a public offering price of $7.00 per share.

October 24, 2018
·
2 min read
Drug Development

Eli Lilly and Pfizer’s Osteoarthritis Drug Dazzles in Phase III

Eli Lilly and Company and Pfizer presented complete results from a Phase III clinical trial of tanezumab in patients with osteoarthritis (OA) at the 2018 American College of Rheumatology/Association of Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting in Chicago.

October 24, 2018
·
3 min read
·
Mark Terry
Drug Development

BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD

BioArctic AB announced today that Eisai will present additional data on the anti-amyloid (Aβ) protofibril antibody BAN2401 clinical Phase 2b study at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference, October 24-27, 2018 in Barcelona, Spain.

October 24, 2018
·
5 min read
Drug Development

Bayer Plans to Seek Approval for Prostate Drug That Hit the Mark in Phase III Trial

A prostate cancer drug jointly developed by healthcare giant Bayer and Finland-based Orion can slow the spread of the disease, according to late-stage study results announced early Wednesday.

October 24, 2018
·
2 min read
·
Alex Keown
Drug Development

Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease

The SEECASE trial met its prespecified primary endpoint for both treatment schedules at 8 weeks

October 24, 2018
·
5 min read
Drug Development

Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint

The safety and tolerability observed in the trial were consistent with previously published data on darolutamide.

October 24, 2018
·
5 min read
Business

Orexo Appoints Joseph DeFeo as New CFO

Orexo AB announces today that the company appoints Joseph DeFeo as the company’s new Chief Financial Officer (CFO) from November 1, 2018.

October 24, 2018
·
2 min read